Behavioral and psychological symptoms of dementia in different dementia disorders: A large-scale study of 12 000 individuals

Emilia Schwertner MSc, Joana B. Pereira PhD[1,2,] Hong Xu PhD[1], Juraj Secnik PhD[1], Bengt Winblad PhD[4,5], Maria Eriksdotter PhD[1,5], Katarina Nagga PhD[2,3]*, Dorota Religa PhD[1,5]*

*K.N. and D.R. contributed equally as senior authors

[1]Center for Alzheimer Research, Division of Clinical Geriatrics, Department of Neurobiology, Department of Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden.

[2] Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden.

[3]Department of Acute Internal Medicine and Geriatrics, Linköping University, Linköping, Sweden.

[4]Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.

[5]Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Corresponding author: Emilia Schwertner

Email: emilia.schwertner@ki.se

Address: Blickagången 16, 14152 Huddinge

Phone: +46 700377353

Funding sources:
SveDem is supported financially by he Swedish Associations of Local Authorities and Regions, Gun och Bertil Stohnes Stiftelse, CIMED grant, Alzheimerfonden, Swedish Brain Foundation, and Margaretha af Ugglas' foundation and Swedish Research Council (Drn 2012-2291 and Drn 2016-02317), and by grants provided by the Stockholm County Council (ALF project).

Acknowledgements:

The authors are grateful to the Swedish Dementia Registry (SveDem, www.svedem.se). We thank all patients, caregivers, reporting units and coordinators in SveDem as well as SveDem steering committee.

Abstract

Objective:

To characterize behavioral and psychological symptoms of dementia (BPSD) in different dementia diagnoses: Alzheimer's disease (AD), dementia with Lewy bodies (DLB), Parkinson´s disease dementia (PDD), vascular dementia (VaD), frontotemporal dementia (FTD), mixed (Mixed) and unspecified dementia.

Design:

Registry-based cohort study.

Setting and participants:

12,137 individuals with dementia registered in two national quality registries, the Swedish registry for cognitive/dementia disorders (SveDem) and the Swedish BPSD registry, during 2010 - 2016.

Methods:

BPSD was assessed with the Neuropsychiatric Inventory - Nursing Home Version (NPI-NH). Multivariate logistic regression models were used to evaluate the associations between dementia diagnoses and different BPSDs in reference to a) the AD group and b) each of the other diagnostic groups. All models were adjusted for age, gender, the severity of cognitive impairment at the time of dementia diagnosis, and time between dementia diagnosis and BPSD assessment.

Results:

In all individuals, the three most common symptoms were aberrant motor behaviour (35,1%), agitation (32,3%), and irritability (28,7%), while euphoria (5,9%) was the least frequent. Compared to AD, we found a lower risk of delusions (in VaD, FTD, unspecified dementia), hallucinations (in VaD and FTD), agitation (in PDD, unspecified dementia), elation/euphoria (in DLB), anxiety (in PDD, unspecified dementia), disinhibition (in PDD); irritability (in DLB, PDD, unspecified dementia), aberrant motor behavior (in Mixed, VaD, unspecified dementia) and sleep and night-time behavior changes (in unspecified dementia). Higher risks of delusions (in DLB), hallucinations (in DLB, PDD), apathy (VaD, FTD), disinhibition (in FTD) and appetite and eating abnormalities (in FTD) were found compared to AD.

Conclusions and Implications:

In this large contemporary cohort, BPSD was common in all types of dementia, with the most common symptoms being aberrant motor behavior, agitation, and irritability. Additionally, BPSD differed depending on the dementia type.

Introduction

Dementia is a complex syndrome associated with cognitive, behavioral, and psychological symptoms. The current diagnostic system emphasizes cognitive impairment and progressive cognitive decline as the key features of dementia.[1] However, cognitive impairment does not solely explain functional disability or poor quality of life in people with dementia. Instead, recent studies have shown that approximately 90% of individuals with dementia will suffer from additional psychological or behavioral symptoms and that these symptoms are the most important factors contributing to functional impairment and increased caregiver burden.[2–5] Behavioral and psychological symptoms of dementia (BPSD) (also referred to as neuropsychiatric symptoms of dementia) include changes in behavior, perception, content of thoughts as well as mood disorders.[5] These symptoms are commonly found across different dementia disorders such as Alzheimer's disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), Parkinson´s disease dementia (PDD) or frontotemporal dementia (FTD). However, studies assessing the prevalence of BPSD in different dementias have reported inconclusive findings. These conflicting results may be attributed to differences in study settings, population demographics, small sample sizes, evaluation methods or the severity of cognitive impairment. Recently, there has been an increasing effort to place BPSD in a more central position in dementia.[6,7] Although studies have reported the presence of these symptoms in AD, VaD, DLB, PDD and FTD, these studies are limited by the lack of comparison of BPSD symptoms between different dementia disorders. Additionally, to our knowledge, the majority of previous studies were conducted in outpatient populations. Presentation of BPSD can differ between community- dwelling individuals and residents of long-term care facilities. For instance, in AD, the study setting was shown to affect the prevalence of irritability, aberrant motor behaviour, euphoria and appetite disorders.[8] These symptoms might be difficult to manage in a home setting and therefore they significantly contribute to the decision of moving a patient to a long-term care facility.[9,10] The aim of this study was to provide a detailed and comprehensive description of presence of BPSD across different dementia diagnoses through a merge of two large Swedish quality registries, mainly encompassing long term care residents.

Materials and Methods

The Swedish registry for cognitive/dementia disorders (SveDem) was established in 2007 and focuses on improving the quality of care of persons with dementia. Individuals are registered at the time of the dementia diagnosis and during follow-up annually in specialist units, primary care centers or in long-term care facilities. Data on type of dementia, age, sex and Mini–Mental State Examination (MMSE) scores at the time of the dementia diagnosis, medication, and living arrangements are collected. Eight types of dementia diagnosis are registered: AD, Mixed, VaD, DLB, PDD, FTD, Unspecified dementia, and other dementia types (including various dementia disorders e.g. corticobasal degeneration and alcohol-related dementia). For a more detailed description of SveDem please see Religa et al.[11]

The Swedish BPSD registry was established in 2010 to improve the quality of care of persons with dementia with BPSD and to achieve a national standard of care for these people throughout Sweden. It includes information about BPSD, current medical treatment and a checklist for possible causes of BPSD.[13] In the registry, assessment of BPSD is carried out using the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH),[14] which includes twelve categories of neuropsychiatric symptoms: delusions, hallucinations, agitation/aggression, depression/depression, apathy, elation/euphoria, anxiety, disinhibition, irritability, aberrant motor behavior, sleep and night-time behavior changes, appetite and eating abnormalities. The NPI-NH is based on the information provided by a caregiver familiar with the behavior of an individual. First, the frequency of symptoms is scored on a four-point scale from 1 to 4 (1: occasionally, 2: less than once a week, 3: very frequently, 4: more than once a day). Second, the severity of the behavior is rated on a three-point scale: mild, moderate, or severe. By multiplying the frequency and severity scores, the NPI-NH yields a rating for each category between 1 and 12. The total NPI score is calculated by adding up the scores across all categories, which can yield a maximum of 144 points. Domain scores of 4 or more are treated as indicative of clinical significance.[15] Information about medical treatment is collected at the time of BPSD assessment. Specifically, the Anatomical Therapeutic Chemical (ATC) codes for the following medications were recorded: analgesics, antipsychotics (ATC code: N05A), anxiolytics (N05B), hypnotics (N05C), antidepressants (N06AA), acetylcholinesterase inhibitors (AChEI) (N06DA), N-Methyl-D-aspartate (NMDA) receptor antagonist (ATC codes: N06DX). At the time of the merge 85.7% of individuals was living in long-term care facilities. Study has ethical approval (2015/2291-31/5).

Study sample size

In 2016, there were 44 482 persons registered in the BPSD registry and 68 515 in SveDem. After merging the two registries, 13 413 individuals with different dementia diagnosis and assessed for BPSD-symptoms were identified. Age was recorded at the time of dementia diagnosis and at the time of registration in the BPSD-registry. After excluding individuals with incomplete records (n=256), duplicates (n=111), diagnoses prior to 2007 (n=81) and after 2017 (n=1), there were 12 964 individuals. For the purposes of the current study, we additionally excluded persons with other types of dementia (n=329) and individuals who were included in the BPSD registry before being registered in SveDem (n=498). As a result, our final study sample consisted of 12 137 individuals (Supplementary Figure 1).

Statistical analyses

Continuous variables were reported as mean ± standard deviation (SD), and categorical variables as counts and proportions. Baseline variables from SveDem and BPSD registries were compared across different dementias by Pearson chi-square for proportions and ANOVA for continuous variables. We used multiple imputations with chained equation (MICE) to account for the effect of missing data in the fully adjusted models.[16] The following variables were used in the imputation model: age, sex, MMSE at the time of dementia diagnosis, type of dementia, time between registration in SveDem and BPSD registries, and NPI scores for the 12 BPSD domains. A summary of all missing data is presented in Supplementary Table 1. Incomplete variables were imputed under fully conditional specification using the mice 3.0 package.[17] We created five multiple imputed datasets and performed multivariate logistic regression analyses in each of them.

Odds ratios (OR) and 95% Confidence Intervals (CIs) of having a clinically significant BPSD (NPI score > 3 in a given domain or category) for each of the 12 symptoms were estimated in each imputed dataset separately and combined using Rubin's rules.[18] All analyses were adjusted for age, sex, MMSE and time between SveDem and BPSD registries. First, we analyzed symptoms comparing each of the diagnoses to AD. Then, to compare symptoms between diagnoses, analyses were repeated with each diagnosis used as a reference group. Given that the main analyses were based on imputed variables, we also performed a sensitivity analysis using only complete cases to assess whether the results were similar before and after imputation. Analyses was performed using R (version 3.6.0).[19]

Results

Overall the most common diagnosis in the cohort was AD (33.5%) the sample, followed by VaD (16.5%), Mixed (15.9%), DLB (2.3%), PDD (1.2%), and FTD (1.9%). Further, there were 28.7% individuals with Unspecified Dementia. Mean+ age at the time of dementia diagnosis was 80.1 ± 7.9 years and 63.5% were women. At the time of dementia diagnosis, 7.0% were being treated with antipsychotics, 30.5% with antidepressants, 18.4% with hypnotics and 13.1% with anxiolytics. Further, 44.6% were being treated with AChEI and 11.0% with NMDA antagonist. A combined AChEI and NMDA antagonist treatment was prescribed to 1.5% individuals. In AD, 69.5% individuals were treated with AChEI, 11.9% with a NMDA antagonist and 2.4% were receiving both NMDA and AChEI. On average, individuals were registered in the BPSD registry after 996 ± 659.8 days from registration in SveDem.

When registered in the BPSD registry, the mean age was 82.3±7.6 years, 16.0% of individuals were being treated with antipsychotics, 42.9% with antidepressants, 18.0% with hypnotics and 18.6% with anxiolytics. In addition, 26.9% were receiving AChEI and 22.3% a NMDA antagonist. A combination of AChEI and NMDA antagonist were prescribed to 7.7% of individuals. In AD, 39.3% were treated with AChEI, 29,6% with NMDA antagonist and 12.6% were receiving both. Mean± of total NPI score was 22.5±21.8 points.

At least one clinically significant symptom (NPI score > 3 in a given domain) was present in 72.3% of individuals and any symptom (NPI score > 0 in a given domain) was present in 91.1% individuals. The most frequent clinically significant symptoms were aberrant motor behavior (35.1%), agitation (32.3%) and irritability (28.7%) (Table 3). The highest mean (SD) total NPI score was found in FTD (Mean = 26.3, SD= 22.6), followed by DLB (Mean = 25.1, SD =23.5), AD (Mean = 24.2, SD = 22.4), PDD (Mean = 21.7, SD = 19.0), Mixed (Mean = 21.9, SD = 21.8), VaD (Mean = 21.6, SD = 21.2) and unspecified dementia (Mean = 21.1, SD = 21). The characteristics of the sample are provided in Tables 1 and 2.

Associations between dementia type and BPSD

The most common clinically significant symptoms in all dementias were aberrant motor behavior, agitation/aggression and irritability, except for DLB and PDD. In DLB,

hallucinations, aberrant motor behavior and delusions were the most frequent symptoms, whereas in PDD aberrant motor behavior, hallucinations and delusions were the most frequent (Fig 1, Table 3). The multivariate logistic regression analyses showed that, compared to AD, individuals with Mixed dementia had lower risk of aberrant motor behavior; individuals with VaD had lower risk of delusions, hallucinations and aberrant motor behavior but higher risk of apathy; individuals with DLB had higher risk of delusions and hallucinations and lower risk of euphoria and irritability; individuals with PDD had higher risk of hallucinations and lower risk of agitation/aggression and anxiety, disinhibition, irritability; individuals with FTD had lower risk of delusions, hallucinations and higher risk of apathy, disinhibition and appetite and eating abnormalities; individuals with unspecified dementia had lower risk of delusions, agitation/aggression, depression/dysphoria, anxiety, irritability, aberrant motor behavior and sleep and night-time behavior changes (Table 4).

We obtained similar results when the analyses were restricted to the cases with complete data in all variables (Supplementary Table 2). The OR 95% (CI) and p-values for comparisons between other diagnoses are presented in Supplementary Tables 3a-f. The summary of these differences has been represented in Supplementary Table 4.

Discussion

In this large-scale study of 12 000 individuals, we observed that BPSD was common across all dementia types, with 72% of all individuals exhibiting at least one clinically significant BPSD. Amongst all symptoms, aberrant motor behaviour, agitation and irritability were the most frequent, occurring commonly in all dementias. It has been suggested that brain regions underlying these symptoms might be associated with problems in the inhibition of one's actions.[20] Moreover, hyperactivity symptoms may be the most important reason of moving to a nursing home and therefore their occurrence may be higher in care facilities.[21] These findings highlight the need of developing strategies for more efficient interventions for these BPSD in long-term facilities.

Associations between dementia type and BPSD

The main aim of this study was to compare BPSD in different dementia diagnoses. Due to their similar presentation of BPSD, AD, Mixed and VaD are discussed as one group and DLB and PDD as another group.

Alzheimer disease, Mixed dementia and Vascular dementia

In the present study, the most common symptoms in AD, Mixed, VaD were aberrant motor behavior, agitation/aggression and irritability. We found that AD individuals had a higher risk of aberrant motor behavior compared with Mixed and VaD as well as delusions and hallucinations in comparison with VaD. Individuals with VaD had higher risk of apathy in comparison to AD. No differences were found between Mixed and VaD. Although previous studies explored the differences between AD, Mixed and VaD,[22–30] their results were not conclusive. Additionally, to our knowledge only three of the previous studies used analyses adjusted for potential confounders[25,27,28] of which two used NPI to assess the symptoms.[27,28] Our study is in line with the work by Caputo et al. (2008)[28] regarding a higher risk of aberrant motor behavior and psychotic symptoms in AD than in VaD. In the study by Fuh et al. (2005)[27] the mean composite scores in the apathy and sleep disturbance domains in individuals with cortical VaD were significantly higher than those in the individuals with AD. However, in our studies it was not possible to differentiate between different subtypes of VaD, which could explain why we did not find similar results as our VaD patients included individuals with both cortical and subcortical pathology.

Dementia with Lewy bodies and Parkinson´s disease dementia

Although DLB and PDD share the core characteristics of DLB (hallucinations, cognitive fluctuations, dementia and parkinsonism)[31], previous studies observed a higher mean total NPI score as well as higher frequencies of delusions, hallucinations, agitation, anxiety, irritability, aberrant motor behavior in DLB compared to PDD.[32–34] In our study, apart from a lower risk of agitation/aggression in individuals with PDD, we did not find any other difference between these two diagnoses. In line with previous reports, a higher risk of hallucinations and delusions in DLB than in other diagnoses was also found in our study.[28,35,36] On the other hand, we found that individuals with DLB had a lower risk of elation/euphoria relative to all other types of dementia, except for PDD. Individuals with PDD had a higher risk of hallucinations (but not delusions) than other types of dementia and a higher risk of aberrant motor behavior than Mixed and VaD. On the other hand, they also had a lower risk of anxiety and other symptoms from the hyperactivity spectrum

(agitation/aggression, disinhibition and irritability). This is in line with previous studies reporting a higher rate of mania and agitation, disinhibition, irritability, euphoria, and apathy in individuals with AD than those with PDD.[37] However, unlike previous studies, a higher rate of depression in PDD than in AD[38] and more severe aberrant motor behavior in AD[37] were not detected in our cohort.

Frontotemporal dementia

The most frequent symptoms in FTD were aberrant motor behavior, agitation/aggression, irritability and apathy. Furthermore, a higher risk of apathy, disinhibition, appetite and eating abnormalities and lower risk of psychotic symptoms was found in this group compared with the other dementia diagnoses. Our results on FTD confirm previous findings.[29,35,39–42]There is consistent evidence showing that in individuals with FTD, apathy, disinhibition and appetite and eating abnormalities are frequent symptoms, with abnormal behavior being the core diagnostic feature of FTD.[43] Moreover, in FTD, behavioral changes are one of the core symptoms of the disease, which explains the highest total NPI score found in our study in this group.

Unspecified dementia

Aberrant motor behavior, agitation/aggression and irritability were the most common symptoms in Unspecified dementia. Additionally, the lowest total NPI score was found in this group. This was in line with the lower risk of several symptoms in unspecified dementia compared with other types of dementia. The diagnosis of unspecified dementia is often set in a primary care setting without access to more extensive investigations needed to reveal the etiology of dementia.[44] The Unspecified dementia group may therefore include people with various pathologies.

General discussion and limitations

Our study was based on the merging of two large quality registries, which enabled sensitive comparison of BPSD between all major subtypes of dementia in a single study. To our knowledge, this is the most comprehensive study on BPSD performed so far. Similar profiles of BPSD in AD, Mixed, VaD and DLB and PDD could be explained by shared pathophysiologic mechanisms.[45–47] Moreover, the presence of symptoms in VaD may vary due to the variability of the location and the extension of ischaemic damage.[48] The VaD cohort in our study was heterogenous and included cases with multi-infarct dementia,

strategic infarct dementia as well as subcortical ischemic dementia. There is also a frequent coexistence of Alzheimer's disease pathology with VaD, DLB and PDD.[45–47] Additionally, potential diagnostic accuracy problems could contribute to these results. For example, some DLB individuals may be misdiagnosed as AD and vice-versa. Moreover, information about the severity of dementia at the time of assessment of BPSD was not available and therefore we used the measurement at the time of dementia diagnosis. The cross-sectional design with a single BPSD measure may obscure differences between different dementia diagnoses. Therefore, a longitudinal design with repeated BPSD assessments should complement the present study. The different sample sizes and their characteristics, study designs and methods to estimate BPSD used in previous studies render the comparisons between our results and previous findings difficult. For instance, in contrast to most previous studies, the majority of individuals in our cohort was older and were mainly residents in long-term care facilities. Furthermore, we cannot rule out that the differences between our and previous studies are due to cultural variation in BPSD.[49] Moreover, we had a fraction of missing data, which was dealt with using the multiple imputation method.

Conclusions and Implications

In this study, BPSD were frequent in all major types of dementias. The most frequent BPSD were agitation/aggression, aberrant motor behavior and irritability, which might be explained by the fact that the majority of individuals in our study were residents in long-term facilities. Additionally, we identified differences in individual BPSD between the dementia diagnoses. Description of BPSD in individuals with dementia may allow for a better understanding of the pathophysiology of the disorder itself. Furthermore, it will also contribute to more personalized care and better quality of individuals with dementia and their caregivers.

The authors declare no conflicts of interest.

References

1. American Psychiatric Associa. *American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)*. VA; 2013.
2. Okabe K, Nagata T, Shinagawa S, et al. Effects of neuropsychiatric symptoms of dementia on reductions in activities of daily living in patients with Alzheimer's disease. *Geriatr Gerontol Int*. 2020;20(6):584-588. doi:10.1111/ggi.13918
3. Moheb N, Mendez MF, Kremen SA, Teng E. Executive Dysfunction and Behavioral Symptoms Are Associated with Deficits in Instrumental Activities of Daily Living in Frontotemporal Dementia. *Dement Geriatr Cogn Disord*. 2017;43(1-2):89-99. doi:10.1159/000455119
4. Baharudin AD, Din NC, Subramaniam P, Razali R. The associations between behavioral-psychological symptoms of dementia (BPSD) and coping strategy, burden of care and personality style among low-income caregivers of patients with dementia. *BMC Public Health*. 2019;19(S4):447. doi:10.1186/s12889-019-6868-0
5. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and Psychological Symptoms of Dementia. *Front Neurol*. 2012;3. doi:10.3389/fneur.2012.00073
6. Wolinsky D, Drake K, Bostwick J. Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease. *Curr Psychiatry Rep*. 2018;20(12):117. doi:10.1007/s11920-018-0978-8
7. Pérez Romero A, González Garrido S. The importance of behavioural and pyschological symptoms in Alzheimer disease. *Neurol Engl Ed*. 2018;33(6):378-384. doi:10.1016/j.nrleng.2016.02.026
8. Zhao Q-F, Tan L, Wang H-F, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. *J Affect Disord*. 2016;190:264-271. doi:10.1016/j.jad.2015.09.069
9. Toot S, Swinson T, Devine M, Challis D, Orrell M. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. *Int Psychogeriatr*. 2017;29(2):195-208. doi:10.1017/S1041610216001654
10. Magierski R, Sobow T, Schwertner E, Religa D. Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress. *Front Pharmacol*. 2020;11:1168. doi:10.3389/fphar.2020.01168
11. Religa D, Fereshtehnejad S-M, Cermakova P, et al. SveDem, the Swedish Dementia Registry – A Tool for Improving the Quality of Diagnostics, Treatment and Care of Dementia Patients in Clinical Practice. Quinn TJ, ed. *PLOS ONE*. 2015;10(2):e0116538. doi:10.1371/journal.pone.0116538
12. Cermakova P, Fereshtehnejad S-M, Johnell K, Winblad B, Eriksdotter M, Religa D. Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry. *Alzheimers Res Ther*. 2014;6(3):34. doi:10.1186/alzrt264
13. Bränsvik V, Granvik E, Minthon L, Nordström P, Nägga K. Mortality in patients with behavioural and psychological symptoms of dementia: a registry-based study. *Aging Ment Health*. Published online February 18, 2020:1-9. doi:10.1080/13607863.2020.1727848
14. Wood S, Cummings JL, Hsu M-A, et al. The Use of the Neuropsychiatric Inventory in Nursing Home Residents: Characterization and Measurement. *Am J Geriatr Psychiatry*. 2000;8(1):75-83. doi:10.1097/00019442-200002000-00010

15. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of Neuropsychiatric Symptoms in Dementia and Mild Cognitive Impairment: Results From the Cardiovascular Health Study. *JAMA*. 2002;288(12):1475. doi:10.1001/jama.288.12.1475
16. Van Buuren S. *Flexible Imputation of Missing Data. Second Edition.* CRC/Chapman & Hall, FL:Boca Raton
17. Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *J Stat Softw*. 45(3):1-67.
18. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. John Wiley and Sons; 1987.
19. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/. Published online 2013.
20. Keszycki RM, Fisher DW, Dong H. The Hyperactivity–Impulsivity–Irritiability–Disinhibition–Aggression–Agitation Domain in Alzheimer's Disease: Current Management and Future Directions. *Front Pharmacol*. 2019;10:1109. doi:10.3389/fphar.2019.01109
21. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. *Int J Geriatr Psychiatry*. 2001;16(1):39-44. doi:10.1002/1099-1166(200101)16:1<39::aid-gps269>3.0.co;2-f
22. Anor CJ, O'Connor S, Saund A, Tang-Wai DF, Keren R, Tartaglia MC. Neuropsychiatric Symptoms in Alzheimer Disease, Vascular Dementia, and Mixed Dementia. *Neurodegener Dis*. 2017;17(4-5):127-134. doi:10.1159/000455127
23. D'Onofrio G, Sancarlo D, Panza F, et al. Neuropsychiatric Symptoms and Functional Status in Alzheimer's Disease and Vascular Dementia Patients. *Curr Alzheimer Res*. 2012;9(6):759-771. doi:10.2174/156720512801322582
24. Ballard C, Neill D, O'Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. *J Affect Disord*. 2000;59(2):97-106. doi:10.1016/S0165-0327(99)00057-9
25. Chiu M-J, Chen T-F, Yip P-K, Hua M-S, Tang L-Y. Behavioral and psychologic symptoms in different types of dementia. *J Formos Med Assoc Taiwan Yi Zhi*. 2006;105(7):556-562. doi:10.1016/S0929-6646(09)60150-9
26. Lyketsos CG. Mental and Behavioral Disturbances in Dementia: Findings From the Cache County Study on Memory in Aging. *Am J Psychiatry*. 2000;157(5):708-714. doi:10.1176/appi.ajp.157.5.708
27. Fuh J-L. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. *J Neurol Neurosurg Psychiatry*. 2005;76(10):1337-1341. doi:10.1136/jnnp.2004.056408
28. Caputo M, Monastero R, Mariani E, et al. Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. *Acta Psychiatr Scand*. 2008;117(6):455-464. doi:10.1111/j.1600-0447.2008.01175.x
29. Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer's disease, vascular dementia and frontotemporal dementia. *J Neurol Sci*. 2005;236(1-2):43-48. doi:10.1016/j.jns.2005.04.014
30. Fernandez-Martinez M, Castro J, Molano A, Zarranz J, Rodrigo R, Ortega R. Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia. *Curr Alzheimer Res*. 2008;5(1):61-69. doi:10.2174/156720508783884585
31. Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies – current issues and future directions. *J Neurochem*. 2019;150(5):467-474. doi:10.1111/jnc.14698

32. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. *Int J Geriatr Psychiatry*. 2001;16(5):528-536. doi:10.1002/gps.389
33. Chiu P-Y, Tsai C-T, Chen P-K, Chen W-J, Lai T-J. Neuropsychiatric Symptoms in Parkinson's Disease Dementia Are More Similar to Alzheimer's Disease than Dementia with Lewy Bodies: A Case-Control Study. Brucki S, ed. *PLOS ONE*. 2016;11(4):e0153989. doi:10.1371/journal.pone.0153989
34. Bougea A, Stefanis L, Paraskevas GP, et al. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease. *J Neurol*. 2018;265(10):2295-2301. doi:10.1007/s00415-018-8992-7
35. Perri R, Monaco M, Fadda L, Caltagirone C, Carlesimo GA. Neuropsychological correlates of behavioral symptoms in Alzheimer's disease, frontal variant of frontotemporal, subcortical vascular, and lewy body dementias: a comparative study. *J Alzheimers Dis JAD*. 2014;39(3):669-677. doi:10.3233/JAD-131337
36. Hashimoto M, Yatabe Y, Ishikawa T, et al. Relationship between Dementia Severity and Behavioral and Psychological Symptoms of Dementia in Dementia with Lewy Bodies and Alzheimer's Disease Patients. *Dement Geriatr Cogn Disord Extra*. 2015;5(2):244-252. doi:10.1159/000381800
37. Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. *Int J Geriatr Psychiatry*. 2001;16(2):184-191. doi:10.1002/1099-1166(200102)16:2<184::aid-gps304>3.0.co;2-k
38. Starkstein SE, Sabe L, Petracca G, et al. Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. *J Neurol Neurosurg Psychiatry*. 1996;61(4):381-387. doi:10.1136/jnnp.61.4.381
39. Levy ML. Alzheimer Disease and Frontotemporal Dementias: Behavioral Distinctions. *Arch Neurol*. 1996;53(7):687. doi:10.1001/archneur.1996.00550070129021
40. Rozzini L, Lussignoli G, Padovani A, Bianchetti A, Trabucchi M. Alzheimer Disease and Frontotemporal Dementia. *Arch Neurol*. 1997;54(4):350-350. doi:10.1001/archneur.1997.00550160005001
41. Bozeat S. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? *J Neurol Neurosurg Psychiatry*. 2000;69(2):178-186. doi:10.1136/jnnp.69.2.178
42. Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral Differences Between Frontotemporal Dementia and Alzheimer's Disease: A Comparison on the BEHAVE-AD Rating Scale. *Int Psychogeriatr*. 1998;10(2):155-162. doi:10.1017/S1041610298005262
43. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. *J Neurol Neurosurg Psychiatry*. 1994;57:416-418.
44. Cermakova P, Johnell K, Fastbom J, et al. Cardiovascular Diseases in ~30,000 Patients in the Swedish Dementia Registry. Giannopoulos S, ed. *J Alzheimers Dis*. 2015;48(4):949-958. doi:10.3233/JAD-150499
45. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol (Berl)*. 2017;134(2):171-186. doi:10.1007/s00401-017-1717-7
46. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. *Neurology*. 2003;60(10):1586-1590. doi:10.1212/01.wnl.0000065889.42856.f2

47. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. *Arch Neurol*. 2002;59(1):102-112. doi:10.1001/archneur.59.1.102
48. Moretti R, Torre P, Antonello RM, Cazzato G. Behavioral alterations and vascular dementia. *The Neurologist*. 2006;12(1):43-47. doi:10.1097/01.nrl.0000186806.54314.e8
49. Shah A, Dalvi M, Thompson T. Behavioural and psychological signs and symptoms of dementia across cultures: current status and the future. *Int J Geriatr Psychiatry*. 2005;20(12):1187-1195. doi:10.1002/gps.1417

FIGURE 1. PERCENTAGE OF CLINICALLY SIGNIFICANT SYMPTOMS (>3) IN DIFFERENT DEMENTIA DIAGNOSES.





Abbreviations: AMB - Aberrant motor behaviour, Sleep - Sleep and night-time behavior changes, Appetite - Appetite and eating abnormalities.

TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION AT THE TIME OF REGISTRATION IN SVEDEM.

	Total	AD	Mixed	VaD	DLB	PDD	FTD	Unspecified	p-value
		4070 (33.5)	925 (15.9)	2007 (16.5)	279 (2.3)	144 (1.2)	227 (1.9)	3485 (28.7)	
Female	7712 (63.5)	2764 (67.9)	238 (64.3)	1159 (57.7)	133 (47.7)	54 (37.5)	123 (54.2)	2241 (64.3)	<0.001
Age, years	80.1 (7.9)	78.2 (8.3)	81.2 (6.7)	81.2 (7.3)	77.6 (7)	75.7 (7.1)	70 (9.2)	82.1 (7.2)	<0.001
MMSE, score	20.2 (5.1)	20.5 (5.1)	20.1 (4.9)	20.2 (4.9)	21.2 (4.9)	20.6 (4.2)	22.3 (5.9)	19.5 (5.2)	<0.001
Time, days to registration in the BPSD-registry	996 (659.8)	1154.4 (681.2)	897.5 (599.8)	880.9 (583.9)	875.6 (612.5)	939.9 (574.3)	914.8 (629.2)	874.7 (616.8)	<0.001
Living arrangement									
Alone	5407 (45.2)	1797 (44.6)	928 (48.6)	901 (45.4)	91 (32.7)	34 (23.8)	72 (32)	1584 (46.6)	<0.001
With somebody	4907 (41)	1873 (46.5)	778 (40.7)	714 (36)	148 (53.2)	87 (60.8)	126 (56)	1181 (34.7)	
Long-term care facilities	1654 (13.8)	355 (8.8)	205 (10.7)	369 (18.6)	39 (14)	22 (15.4)	27 (12)	637 (18.7)	
Antipsychotics	801 (7)	204 (5.3)	125 (6.7)	128 (6.7)	35 (12.8)	28 (20.7)	28 (12.5)	253 (8)	<0.001
Anxiolytics	1500 (13.1)	390 (10)	195 (10.4)	291 (15.2)	32 (11.6)	17 (12.5)	27 (12.1)	548 (17.4)	<0.001
Hypnotics	2105 (18.4)	603 (15.5)	329 (17.7)	408 (21.4)	61 (22.1)	23 (17)	33 (14.7)	648 (20.6)	<0.001
Antidepressants	3500 (30.5)	1145 (29.4)	502 (26.8)	676 (35.2)	100 (36.2)	51 (37.2)	79 (35)	947 (29.9)	<0.001
AChEI	5191 (44.6)	2751 (69.5)	938 (49.7)	176 (9.1)	204 (73.4)	74 (51.7)	16 (7.1)	1032 (32.1)	<0.001
NMDA antagonist	1271 (11)	465 (11.9)	389 (20.7)	116 (6.1)	48 (17.5)	26 (18.8)	18 (8)	209 (6.6)	<0.001
NMDA antagonist + AChEIs	182 (1.5)	99 (2.4)	24 (1.3)	5 (0.2)	17 (6.2)	10 (7.2)	2 (0.9)	25 (0.7)	<0.001

Abbreviations: AD - Alzheimer Disease; Mixed - Mixed Dementia; VaD – Vascular dementia; DLB – Dementia with Lewy Bodies; PDD- Parkinson´s disease dementia; FTD – Frontotemporal dementia; MMSE - Mini-Mental State Examination; Living arrangement - at the time of dementia diagnoses; NMDA - N-Methyl-D-aspartate, AChEIs - Acetylcholineesterase inhibitors. Data are presented as mean (SD) or n (%).

TABLE 2. BASIC CHARACTERISTICS OF THE STUDY POPULATION AT THE TIME OF REGISTRATION IN THE BPSD REGISTRY.

	Total	AD	Mixed	VaD	DLB	PDD	FTD	Unspecified	p-value
Age	82.3 (7.6)	80.8 (8)	83.3 (6.5)	83 (7.2)	79.4 (6.6)	77.7 (7)	71.8 (9.2)	84 (7)	<0.001
Analgesics	4461 (36.8)	1435 (35.3)	715 (37.1)	779 (38.8)	102 (36.6)	51 (35.4)	62 (27.3)	1317 (37.8)	0.006
Antipsychotics	1940 (16)	677 (16.6)	272 (14.1)	307 (15.3)	53 (19)	37 (25.7)	56 (24.7)	538 (15.4)	<0.001
Anxiolytics	2263 (18.6)	801 (19.7)	344 (17.9)	363 (18.1)	44 (15.8)	14 (9.7)	33 (14.5)	664 (19.1)	0.014
Hypnotics	2187 (18)	731 (18)	388 (20.2)	385 (19.2)	61 (21.9)	18 (12.5)	43 (18.9)	561 (16.1)	0.001
Antidepressants	5211 (42.9)	1805 (44.3)	804 (41.8)	907 (45.2)	120 (43)	64 (44.4)	87 (38.3)	1424 (40.9)	0.010
AChEI	3266 (26.9)	1599 (39.3)	604 (31.4)	143 (7.1)	147 (52.7)	51 (35.4)	12 (5.3)	710 (20.4)	<0.001
NMDA antagonist	2710 (22.3)	1203 (29.6)	583 (30.3)	219 (10.9)	106 (38)	38 (26.4)	24 (10.6)	537 (15.4)	<0.001
NMDA + AChEI	938 (7.7)	514 (12.6)	174 (9)	23 (1.2)	66 (23.7)	16(11.1)	5 (2.2)	140 (4.0)	<0.001
Total NPI	22.5 (21.8)	24.2 (22.4)	21.9 (21.8)	21.6 (21.2)	25.1 (23.6)	21.7 (19.0)	26.3 (22.6)	21.1 (21)	<0.001
Clincally significant symptom (NPI >3)	8600 (72.3)	2981 (74.9)	1356 (72.0)	1379 (69.9)	202 (73.7)	108 (75.5)	176 (79.3)	2398 (70.1)	<0.001
Any symptom (NPI >0)	10851 (91.1)	3656 (91.8)	1715 (90.9)	1772 (89.8)	255 (92.4)	133 (93.0)	209 (94.1)	3111 (90.8)	0.096

Abbreviations: AD - Alzheimer Disease. Mixed - Mixed Dementia, VaD – Vascular dementia, DLB – Dementia with Lewy Bodies, PDD - Parkinson´s disease dementia, FTD – Frontotemporal dementia, NMDA – N-Methyl-D-aspartate, NPI – Neuropsychiatric Inventory. Data are presented as mean (SD) or n (%).

TABLE 3. FREQUENCY OF BPSD IN THE WHOLE COHORT AND IN EACH DEMENTIA

	Total	AD	Mixed	VaD	DLB	PDD	FTD	Unspecified	p-value
Delusions									
Mild symptoms (0-3)	9356 (78.5)	3085 (77.4)	1496 (79.3)	1574 (79.8)	185 (67)	106 (74.1)	193 (86.9)	2717 (79.3)	<0.001
Clinically significant (>3)	2556 (21.5)	899 (22.6)	391 (20.7)	399 (20.2)	91 (33)	37 (25.9)	29 (13.1)	710 (20.7)	
Hallucinations>									
Mild symptoms (0-3)	10312 (86.6)	3434 (86.3)	1655 (87.8)	1757 (89)	171 (62)	100 (69.9)	206 (92.8)	2989 (87.2)	<0.001
Clinically significant (>3)	1594 (13.4)	546 (13.7)	230 (12.2)	217 (11)	105 (38)	43 (30.1)	16 (7.2)	437 (12.8)	
Agitation/Aggression									
Mild symptoms (0-3)	8060 (67.7)	2601 (65.4)	1266 (67.1)	1355 (68.6)	184 (67.2)	112 (78.3)	142 (64)	2400 (70.1)	0.001
Clinically significant (>3)	3845 (32.3)	1379 (34.6)	620 (32.9)	619 (31.4)	90 (32.8)	31 (21.7)	80 (36)	1026 (29.9)	
Depression/Dysphoria									
Mild symptoms (0-3)	9356 (78.6)	3056 (76.8)	1478 (78.4)	1545 (78.3)	217 (78.9)	120 (83.9)	177 (79.7)	2763 (80.7)	0.002
Clinically significant (>3)	2548 (21.4)	923 (23.2)	408 (21.6)	429 (21.7)	58 (21.1)	23 (16.1)	45 (20.3)	662 (19.3)	
Anxiety									
Mild symptoms (0-3)	9126 (76.7)	2941 (73.9)	1462 (77.5)	1514 (76.7)	214 (77.5)	119 (83.2)	170 (76.6)	2706 (79.1)	<0.001
Clinically significant (>3)	2778 (23.3)	1039 (26.1)	424 (22.5)	460 (23.3)	62 (22.5)	24 (16.8)	52 (23.4)	717 (20.9)	
Elation/Euphoria									
Mild symptoms (0-3)	11190 (94.1)	3695 (92.9)	1784 (94.7)	1872 (94.9)	266 (97.1)	135 (94.4)	196 (88.3)	3242 (94.7)	<0.001
Clinically significant (>3)	707 (5.9)	284 (7.1)	100 (5.3)	101 (5.1)	8 (2.9)	8 (5.6)	26 (11.7)	180 (5.3)	
Apathy									
Mild symptoms (0-3)	9713 (81.6)	3231 (81.2)	1556 (82.5)	1601 (81.1)	232 (84.4)	119 (83.2)	153 (68.9)	2821 (82.3)	0.014
Clinically significant (>3)	2190 (18.4)	747 (18.8)	330 (17.5)	372 (18.9)	43 (15.6)	24 (16.8)	69 (31.1)	605 (17.7)	
Disinhibition									

Mild symptoms (0-3)	9988 (83.9)	3315 (83.3)	1579 (83.8)	1658 (84)	237 (86.2)	130 (90.9)	163 (73.4)	2906 (84.9)	<0.001
Clinically significant (>3)	1912 (16.1)	664 (16.7)	306 (16.2)	315 (16)	38 (13.8)	13 (9.1)	59 (26.6)	517 (15.1)	
Irritability									
Mild symptoms (0-3)	8487 (71.3)	2739 (68.9)	1333 (70.7)	1408 (71.4)	208 (75.9)	111 (77.6)	151 (68)	2537 (74.1)	0.015
Clinically significant (>3)	3409 (28.7)	1238 (31.1)	552 (29.3)	564 (28.6)	66 (24.1)	32 (22.4)	71 (32)	886 (25.9)	
Aberrant motor behavior									
Mild symptoms (0-3)	7720 (64.9)	2367 (59.5)	1271 (67.4)	1367 (69.3)	177 (64.4)	79 (55.2)	120 (54.1)	2339 (68.3)	<0.001
Clinically significant (>3)	4182 (35.1)	1614 (40.5)	614 (32.6)	606 (30.7)	98 (35.6)	64 (44.8)	102 (45.9)	1084 (31.7)	
Sleep and night-time behavior changes									
Mild symptoms (0-3)	9826 (82.6)	3281 (82.5)	1551 (82.4)	1614 (81.8)	214 (77.8)	119 (83.2)	187 (84.2)	2860 (83.6)	0.066
Clinically significant (>3)	2066 (17.4)	696 (17.5)	331 (17.6)	358 (18.2)	61 (22.2)	24 (16.8)	35 (15.8)	561 (16.4)	
Appetite and eating abnormalities									
Mild symptoms (0-3)	9698 (81.5)	3212 (80.7)	1560 (82.8)	1611 (81.7)	230 (83.6)	123 (86)	157 (70.7)	2805 (81.9)	0.003
Clinically significant (>3)	2198 (18.5)	767 (19.3)	323 (17.2)	360 (18.3)	45 (16.4)	20 (14)	65 (29.3)	618 (18.1)	

Abbreviations: AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, DLB – Dementia with Lewy Bodies, PDD - Parkinson´s disease dementia, FTD – Frontotemporal dementia. Data are presented as n (%).

TABLE 4. ODDS RATIOS (OR) AND 95% CONFIDENCE INTERVALS (CI) OF THE ASSOCIATION BETWEEN DEMENTIA TYPE AND BPSD WITH THE REFERENCE TO AD

	Dementia Diagnosis											
	Mixed		**VaD**		**DLB**		**PDD**		**FTD**		**Unspecified**	
	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-valu
Delusions	0.89 (0.77-1.02)	0.083	0.86 (0.75-0.98)	0.025	1.7 (1.3-2.22)	<0.001	1.17 (0.8-1.73)	0.415	0.5 (0.33-0.75)	0.001	0.86 (0.77-0.97)	0.012
Hallucinations	0.93 (0.78-1.1)	0.37	0.84 (0.7-1)	0.04	4.15 (3.17-5.43)	<0.001	2.78 (1.91-4.06)	<0.001	0.48 (0.28-0.81)	0.01	0.97 (0.84-1.11)	0.63
Agitation/Aggression	1 (0.88-1.12)	0.949	0.93 (0.83-1.05)	0.257	0.92 (0.71-1.2)	0.543	0.49 (0.32-0.73)	0.001	1.02 (0.76-1.37)	0.889	0.86 (0.78-0.96)	0.005
Depression/Dysphoria	0.97 (0.85-1.12)	0.711	0.99 (0.87-1.14)	0.921	0.89 (0.66-1.21)	0.46	0.66 (0.42-1.05)	0.077	0.71 (0.51-1.01)	0.055	0.85 (0.75-0.95)	0.006
Elation/Euphoria	0.9 (0.71-1.14)	0.379	0.89 (0.7-1.14)	0.356	0.41 (0.2-0.84)	0.014	0.8 (0.38-1.67)	0.549	1.33 (0.85-2.08)	0.216	0.92 (0.75-1.13)	0.434
Anxiety	0.89 (0.78-1.01)	0.074	0.96 (0.84-1.09)	0.524	0.9 (0.67-1.22)	0.507	0.6 (0.38-0.94)	0.027	0.82 (0.59-1.14)	0.242	0.81 (0.72-0.91)	<0.001
Apathy	1.04 (0.9-1.21)	0.581	1.19 (1.03-1.37)	0.017	0.85 (0.61-1.2)	0.361	0.85 (0.54-1.35)	0.498	1.89 (1.39-2.57)	<0.001	1.07 (0.94-1.21)	0.318
Disinhibition	1.06 (0.91-1.23)	0.492	1.01 (0.87-1.18)	0.863	0.77 (0.53-1.1)	0.144	0.45 (0.25-0.81)	0.007	1.46 (1.05-2.03)	0.023	0.96 (0.85-1.1)	0.569
Irritability	1.01 (0.89-1.14)	0.904	0.97 (0.86-1.1)	0.683	0.7 (0.52-0.93)	0.016	0.59 (0.39-0.88)	0.01	0.92 (0.68-1.24)	0.578	0.84 (0.75-0.93)	0.001
Aberrant motor behavior	0.78 (0.69-0.87)	<0.001	0.72 (0.64-0.81)	<0.001	0.79 (0.61-1.03)	0.079	1.06 (0.76-1.5)	0.725	1.01 (0.76-1.34)	0.968	0.76 (0.69-0.84)	<0.001
Sleep and night-time behavior changes	0.97 (0.84-1.12)	0.651	0.98 (0.85-1.13)	0.77	1.2 (0.89-1.62)	0.242	0.78 (0.5-1.23)	0.293	0.84 (0.56-1.25)	0.385	0.88 (0.77-1)	0.045
Appetite and eating abnormalities	0.93 (0.8-1.07)	0.312	1.05 (0.91-1.21)	0.539	0.91 (0.65-1.27)	0.58	0.76 (0.47-1.24)	0.274	1.83 (1.34-2.49)	<0.001	0.99 (0.88-1.12)	0.882

Abbreviations: AD - Alzheimer Disease, Mixed - Mixed Dementia, VaD – Vascular dementia, DLB – Dementia with Lewy Bodies, PDD - Parkinson´s disease dementia, FTD – Frontotemporal dementia. Model adjusted for age, sex, MMSE and time between registration to SveDem and BPSD registry.